Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
| Autor: | Choi SH; Department of Neurology, Inha University College of Medicine, Incheon, South Korea., Kim SY, Na HR, Kim BK, Yang DW, Kwon JC, Park MY |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Dementia and geriatric cognitive disorders [Dement Geriatr Cogn Disord] 2008; Vol. 25 (5), pp. 445-50. Date of Electronic Publication: 2008 Apr 10. |
| DOI: | 10.1159/000124752 |
| Abstrakt: | Background/aims: The possible influence of apolipoprotein E (ApoE) genotype on the response to acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease (AD) remains a matter of controversy. In order to address this issue, we investigated the effects of ApoE genotype on the clinical response to donepezil in patients with mild to moderate AD. Methods: An open study was carried out in 51 patients with probable AD who were treated with 5-10 mg of donepezil per day for 48 weeks. Results: Eighteen (35.3%) of the 51 patients had 1 or 2 ApoE epsilon4 alleles. ApoE epsilon4 carriers with AD showed a mean 1.1-point increase from the baseline score of 23.9 on the 70-point Alzheimer's Disease Assessment Scale-Cognitive Component at 48 weeks, while the ApoE epsilon4 noncarrier group showed a 3.1-point increase from the baseline score of 22.5 (p = 0.03). The ApoE epsilon4 carrier group exhibited a mean 0.13-point worsening from the baseline score of 0.97 on the Korean Instrumental Activities of Daily Living at 48 weeks, while the ApoE epsilon4 noncarrier group exhibited a 0.17-point worsening from the baseline score of 0.64 (p = 0.05). Conclusion: AD patients who carry the ApoE epsilon4 allele may respond more favorably to donepezil than epsilon4 noncarriers. ((c) 2008 S. Karger AG, Basel) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|